百乐眠胶囊联合艾司唑仑治疗失眠症的疗效观察

目的探讨百乐眠胶囊联合艾司唑仑治疗失眠症的临床疗效。方法选取2016-2018年到云浮市人民医院接受治疗的210例失眠症患者,根据给药不同将所有患者分为3组,每组患者70例。百乐眠组口服百乐眠胶囊,4粒/次,2次/d;艾司唑仑组晚上入睡前30 min口服艾司唑仑片,1片/次,1次/d;联合组口服百乐眠胶囊联合艾司唑仑片,相关药物服用方法同以上两组。三组患者均连续治疗2周。观察三组的临床疗效,比较三组患者匹兹堡睡眠质量指数(PSQI)和不良反应发生情况。结果治疗后,百乐眠组、艾司唑仑组、联合组总有效率分别是74.28%、82.86%、97.14%,联合组总有效率显著高于百乐眠组、艾司唑仑组,差异有统计学意义(P<0.05)。治疗后,3组患者PSQI评分均有所降低(P<0.05);但治疗后,联合组患者PSQI各评分均显著低于百乐眠组、艾司唑仑组(P<0.05)。百乐眠组、艾司唑仑组、联合组不良反应发生率分别是8.57%、22.86%、10.00%,艾司唑仑组失眠症患者不良反应发生率明显高于百乐眠组、联合组(P<0.05)。结论百乐眠胶囊联合艾司唑仑治疗失眠症具有较好的临床疗效,可显著降低PSQI评分,改善患者睡眠质量,具有一定的临床推广应用价值。

Clinical observation on Bailemian Capsules combined with estazolam in treatment of insomnia

Objective To analysis the effect of Bailemian Capsules combined with estazolam in treatment of insomnia. Methods 210 Patients with insomnia treated in Yunfu People''s Hospital from 2016 to 2018 were divided into 3 groups according to the different medication methods, and 70 patients in each group. Patients in Bailemian group were po administered with Bailemian Capsules, 4 grains/time, twice daily. Patients in estazolam group were po administered with Estazolam Tablets 30 min before falling asleep at night, 1 tablet/time, once daily. Patients in combination group were po administered with Bailemian Capsules and Estazolam Tablets, and the drug administration methods were the same as the above two groups. Patients in all three groups were treated for 2 weeks. The clinical efficacy of the three groups were observed, PSQI and adverse reactions were compared. Results After treatment, the total effective rates of the Bailemian group, estolam group and the combination group were 74.28%, 82.86% and 97.14%, respectively. The total effective rates of the combination group were significantly higher than that of Bailemian group and estolam group, with statistically significant differences (P<0.05). After treatment, the PSQI scores of all three groups were decreased (P<0.05). However, after treatment, the PSQI scores of the combination group were significantly lower than that of the Bailemian group, the estolam group (P<0.05). The incidence of adverse reactions was 8.57%, 22.86% and 10.00%, respectively, in the Bailemian group, the estolam group and the combination group. The incidence of adverse reactions in the estolam group was significantly higher than that in the Bailemian group and the combination group (P<0.05). Conclusion Bailemian Capsules combined with estazolam has good clinical effect in treatment of insomnia, and can significantly reduce the PSQI score, improve the sleep quality of patients, which has a certain clinical application value.